Cisse M M, Ka E, Gueye S, Seck S M, Tall A, Niang A, Diouf B
Département de Néphrologie, CHU A Le Dantec, Dakar, Sénégal.
Med Trop (Mars). 2011 Oct;71(5):468-71.
Chronic kidney disease is now regarded as amajor public health concern. This is especially true in developing countries where it accounts for significant morbidity, mortality and decreased life expectancy. The main problem for developing countries is the cost of dialysis. Indeed, the availability of peritoneal dialysis for renal replacement therapy is low in sub-Saharan Africa. Since March 2004 peritoneal dialysis has been available to some patients with end-stage renal disease in Senegal. The purpose of this study was to assess epidemiologic, clinical, technical patterns and outcomes in patients who underwent peritoneal dialysis in the first three years of the program.
This three-year retropective study identified 26 patients who underwent peritoneal dialysis for end-stage renal disease for a period of at least 15 days. Patients not meeting these criteria were not included. All patients had a Baxter type transfer set. Lactate-bicarbonate solution was used for countinuous ambulatory peritoneal dialysis. In 3 cases, Icodextrin- and amino-acid based-solutions were employed. In automated peritoneal dialysis, the Home Choice machine was used for all patients. Epidemiological, clinical/paraclinical data and outcomes were noted for each patient.
Twenty-six patients were included in the study. Median age was 48 +/- 6 years with a M/F sex ratio of 1.17. Most patients (84%) were literate. Diabetic nephropathy and nephroangiosclerosis were the main causes of end-stage renal disease. The mean Charlson score was 3 (range, 2 to 5). Mean residual diuresis was 435 mL/day. The peritonitis rate was 1 per 20 patient months. Staphylococcus aureus and Pseudomonas aeruginosa were the most common germs. Six patients presented catheter infection: exit-site in 4 and tunnel in 2. Catheter obstruction occurred in three cases. At the end of the study, 6 patients were still in automated peritoneal dialysis and 8 in countinuous ambulatory peritoneal dialysis. Six 6 patients died and 6 were switched to hemodialysis.
Peritoneal dialysis is available as a renal replacement therapy in Senegal. It has allowed end-stage renal disease patients greater autonomy in their working place.
慢性肾脏病如今被视为一个主要的公共卫生问题。在发展中国家尤其如此,慢性肾脏病在这些国家导致了显著的发病率、死亡率以及预期寿命的降低。发展中国家面临的主要问题是透析费用。事实上,撒哈拉以南非洲地区可用于肾脏替代治疗的腹膜透析的可及性较低。自2004年3月起,塞内加尔的一些终末期肾病患者可以使用腹膜透析。本研究的目的是评估该项目头三年接受腹膜透析的患者的流行病学、临床、技术模式及结局。
这项为期三年的回顾性研究纳入了26例接受腹膜透析治疗终末期肾病至少15天的患者。不符合这些标准的患者未被纳入。所有患者均使用百特(Baxter)型转接套件。乳酸盐 - 碳酸氢盐溶液用于持续性非卧床腹膜透析。3例患者使用了基于艾考糊精和氨基酸的溶液。在自动化腹膜透析中,所有患者均使用Home Choice机器。记录了每位患者的流行病学、临床/辅助临床数据及结局。
26例患者纳入研究。中位年龄为48±6岁,男女比例为1.17。大多数患者(84%)识字。糖尿病肾病和肾血管硬化是终末期肾病的主要病因。查尔森(Charlson)评分均值为3(范围为2至5)。平均残余尿量为435毫升/天。腹膜炎发生率为每20患者月1次。金黄色葡萄球菌和铜绿假单胞菌是最常见的病菌。6例患者出现导管感染:4例为出口处感染,2例为隧道感染。3例发生导管阻塞。研究结束时,6例患者仍在接受自动化腹膜透析,8例在接受持续性非卧床腹膜透析。6例患者死亡,6例转为血液透析。
在塞内加尔,腹膜透析可作为一种肾脏替代治疗方法。它使终末期肾病患者在工作场所拥有了更大的自主性。